AveXis (NASDAQ:AVXS) has been given a $122.00 price objective by equities researchers at UBS Group in a research note issued to investors on Friday. The firm currently has a “buy” rating on the stock. UBS Group’s price objective points to a potential upside of 16.48% from the stock’s current price.
Several other analysts have also commented on AVXS. Citigroup set a $132.00 price objective on shares of AveXis and gave the stock a “buy” rating in a research report on Friday. Canaccord Genuity set a $110.00 price target on shares of AveXis and gave the company a “hold” rating in a research report on Wednesday, December 20th. BMO Capital Markets reissued an “outperform” rating and issued a $123.00 price target on shares of AveXis in a research report on Saturday, September 30th. BidaskClub raised shares of AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Finally, Jefferies Group boosted their price target on shares of AveXis to $118.00 and gave the company a “buy” rating in a research report on Thursday, October 12th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and thirteen have issued a buy rating to the stock. AveXis has a consensus rating of “Buy” and a consensus target price of $111.56.
Shares of AveXis (AVXS) opened at $104.74 on Friday. The company has a market cap of $3,350.00 and a PE ratio of -18.77. AveXis has a 12-month low of $50.56 and a 12-month high of $116.15.
In related news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $109.72, for a total transaction of $195,301.60. Following the sale, the vice president now owns 1,780 shares of the company’s stock, valued at approximately $195,301.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Andrew F. Knudten sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $94.48, for a total transaction of $188,960.00. Following the sale, the vice president now directly owns 7,000 shares in the company, valued at approximately $661,360. The disclosure for this sale can be found here. Insiders have sold a total of 67,340 shares of company stock worth $6,840,745 in the last ninety days. 18.60% of the stock is currently owned by insiders.
A number of institutional investors have recently bought and sold shares of AVXS. Strs Ohio bought a new stake in AveXis during the 3rd quarter worth approximately $116,000. Ameritas Investment Partners Inc. increased its holdings in AveXis by 331.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after acquiring an additional 1,622 shares during the period. Cubist Systematic Strategies LLC increased its holdings in AveXis by 688.6% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after acquiring an additional 1,577 shares during the period. Teacher Retirement System of Texas bought a new stake in AveXis during the 3rd quarter worth approximately $200,000. Finally, Deschutes Portfolio Strategy LLC bought a new stake in AveXis during the 3rd quarter worth approximately $203,000. 92.88% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This piece of content was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3126867/avexis-avxs-given-a-122-00-price-target-by-ubs-group-analysts.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.